EUCTR2006-004481-13-ES进行中（未招募）1 期
Efecto de liraglutida sobre el peso corporal en sujetos obesos sin diabetesEnsayo de 20 semanas de duración, aleatorizado, doble ciego, controlado con placebo, en seis grupos paralelos, multicéntrico, multinacional con una rama abierta de comparación con orlistat con un período de extensión de 84 semanas
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Informed consent obtained prior to any trial-related activities. (Trial-related activities are any procedure that would not have been performed during the normal management of the subject)
- •2.Body Mass Index (BMI) = 30.0 and = 40.0 kg/m2
- •3.Stable body weight (less than 5% self-reported change during the previous 3 months)
- •4.Age between 18 and 65 years (both inclusive)
- •5.Fasting plasma glucose < 7.0 mmol/L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Untreated thyroid disease defined as TSH values outside normal ranges or obesity induced by other known endocrinological disorders
- •2.Obesity induced by drug treatment (e.g. corticosteroids, tricyclic anti-depressants, atypical anti-psychotics)
- •3.Use of approved weight lowering pharmacotherapy (e.g. orlistat, sibutramin, rimonabant) within the last 3 months prior to screening into this trial
- •4.Participation in a clinical study of weight control within the last 3 months prior to screening into this trial
- •5.Previous surgical treatment of obesity
- •6.Subjects with chronic malabsorption syndrome or cholestasis
- •7.Known type 1 or type 2 diabetes
- •8.Surgery scheduled for the trial duration period, except for minor surgical procedures, at the discretion of the Investigator
- •9.Impaired liver function, defined as ALAT = 2.5 times upper limit of normal (one retest analysed at the central laboratory within a week is permitted with the result of the last sample being conclusive)
- •10.Impaired renal function defined as serum-creatinine = 135 µmol/L (= 1.5 mg/dL) for males and = 120 µmol/L (= 1.4 mg/dL) for females (one retest analysed at the central laboratory within a week is permitted with the result of the last sample being conclusive)
- •11.Clinically significant active cardiovascular disease including history of myocardial infarction within the past 6 months and/or heart failure (NYHA class III and IV) at the discretion of the Investigator. (Please refer to Appendix C)
- •12.Uncontrolled treated/untreated hypertension (systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg)
- •13.Any clinically significant disease which in the Investigator’s opinion could interfere with the results of the trial
- •14.Cancer (past or present, except basal cell skin cancer or sqaumous cell skin cancer), which in the Investigator’s opinion could interfere with the results of the trial
- •15.Known or suspected allergy to trial product(s) or related product(s)
- •16.Previous participation in this trial (screening and treatment period)
- •17.Known or suspected abuse of alcohol or narcotics
- •18.Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation
- •19.Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)
- •20.The receipt of any investigational drug within four weeks prior to screening into this trial
研究者
相似试验
进行中（未招募）
不适用
Efecto de liraglutida en el peso corporal en sujetos no diabéticos obesos o con sobrepeso y comorbilidad.Ensayo clínico aleatorizado, doble-ciego, controlado con placebo, grupos paralelos, multicéntrico, multinacional, con estratificación de sujetos a uno o tres años de tratamiento basada en el estatus pre-diabético en la aleatorizacióEUCTR2008-001049-24-ESovo Nordisk A/S4,800
进行中（未招募）
不适用
Efecto de liraglutida en el peso corporal en sujetos con sobrepeso u obesos con diabetes tipo 2. Ensayo clínico de 1 año de duración, aleatorizado, doble-ciego, controlado con placebo, con tres grupos paralelos, multicéntrico, multinacional, con un periodo de seguimiento observacional de 12 semanas.Obesidad y sobrepesoMedDRA version: 9.1Level: LLTClassification code 10029883Term: ObesityMedDRA version: 9.1Level: LLTClassification code 10033307Term: OverweightEUCTR2008-002199-88-ESovo Nordisk A/S1,600
进行中（未招募）
1 期
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebo-controlled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow-up period - SCALE™ - DiabetesObesity and overweightMedDRA version: 14.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.0 Level: PT Classification code 10033307 Term: Overweight System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2008-002199-88-GBovo Nordisk A/S
进行中（未招募）
不适用
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetesA 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow-up period - SCALE™ - DiabetesObesity and overweightMedDRA version: 14.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.0Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2008-002199-88-SEovo Nordisk A/S800
进行中（未招募）
1 期
Effect of liraglutide on body weight in overweight orobese subjects with type 2 diabetesA 1 year randomised, double-blind, placebo-controlled,three armed parallel group, multi-centre, multinationaltrial with a 12 week observational follow-up periodObesity and overweightMedDRA version: 9.1Level: LLTClassification code 10029883Term: ObesityMedDRA version: 9.1Level: LLTClassification code 10033307Term: OverweightEUCTR2008-002199-88-FRovo Nordisk A/S